This is attributed to the fact that Lcn-2 is also able to promote epithelial-to-mesenchymal transition (EMT) and bind to matrix metalloprotease 9 (MMP9), thereby modulating the metastatic phenotype of cancer cells. This evidence concerns the gene LCN2 and cancer.